|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0020789,
umls-concept:C0023467,
umls-concept:C0040808,
umls-concept:C0040845,
umls-concept:C0059985,
umls-concept:C0079459,
umls-concept:C0332281,
umls-concept:C0442967,
umls-concept:C0585361,
umls-concept:C0733521,
umls-concept:C1704419
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2009-5-18
|
|
pubmed:abstractText |
Preclinical data suggest that all-trans retinoic acid (ATRA) synergizing with granulocyte colony stimulating factor (G-CSF), can improve the effectiveness of chemotherapy in acute myeloid leukemia (AML). Fludarabine 15 mg/m(2) is the minimum dose able to optimize intensification with fludarabine-arabinosylcytosine regimen. In this study 52 patients with relapsed/refractory AML obtained a complete remission (CR) rate of 69.2% after FLAIRG regimen (Fludarabine and arabinosylcytosine twice daily, idarubicin, G-CSF, ATRA). This schedule resulted effective and tolerable enabling 53% of the responding patients to receive transplant procedure. FLAIRG regimen could be proposed as a "bridge" to transplant treatment in this poor risk setting.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1873-5835
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
33
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1072-8
|
|
pubmed:meshHeading |
pubmed-meshheading:19187960-Adolescent,
pubmed-meshheading:19187960-Adult,
pubmed-meshheading:19187960-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19187960-Cytarabine,
pubmed-meshheading:19187960-Disease-Free Survival,
pubmed-meshheading:19187960-Female,
pubmed-meshheading:19187960-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:19187960-Humans,
pubmed-meshheading:19187960-Idarubicin,
pubmed-meshheading:19187960-Leukemia, Myeloid, Acute,
pubmed-meshheading:19187960-Male,
pubmed-meshheading:19187960-Middle Aged,
pubmed-meshheading:19187960-Prospective Studies,
pubmed-meshheading:19187960-Remission Induction,
pubmed-meshheading:19187960-Salvage Therapy,
pubmed-meshheading:19187960-Survival Rate,
pubmed-meshheading:19187960-Tretinoin,
pubmed-meshheading:19187960-Vidarabine
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
|
|
pubmed:affiliation |
Department of Oncology/Hematology, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, Milano, Italy. marco.montillo@ospedaleniguarda.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
